Stay updated on Nivolumab Ipilimumab SBRT in Salivary Gland Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab SBRT in Salivary Gland Cancers Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab SBRT in Salivary Gland Cancers Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPage shows a minor version update from v3.3.1 to v3.3.2; no changes to study details, layout, or user-facing content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 is now shown, replacing the previous Revision: v3.2.0. The study details, eligibility criteria, and results remain unchanged.SummaryDifference0.1%

- Check29 days agoChange DetectedThe government funding lapse notice was removed from the page.SummaryDifference0.4%

- Check43 days agoChange DetectedThe screenshots show cosmetic formatting updates and minor textual edits that do not modify the study's core details (interventions, eligibility, endpoints, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference2%

- Check79 days agoChange DetectedCore content and terminology related to immune biology have been expanded (new terms added) and the version updated from v3.0.2 to v3.1.0.SummaryDifference0.9%

Stay in the know with updates to Nivolumab Ipilimumab SBRT in Salivary Gland Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab SBRT in Salivary Gland Cancers Clinical Trial page.